Chateauroux

Researchers are evaluating four different isotonic and hypertonic seawater-based nasal sprays in real-life settings for their effectiveness, safety, usage, tolerance, and user satisfaction. The study focuses on infants, children, adults, and pregnant or breastfeeding women who have acute or chronic sinonasal conditions such as upper respiratory tract infections, allergic rhinitis, chronic rhinosinusitis, bronchiolitis, COVID-19, and post-surgery nasal issues. The investigation aims to understand how these devices perform when used as intended across various patient groups. Participants will use one of four CE-marked nasal spray devices according to their specific indications and target populations. The sprays include Respimer Hygiene-Prevention for babies, kids, and adults, Respimer Decongestion for babies from two months old and older, and Phytosun arms Hypertonic nasal wash for children six years and older and adults. Usage instructions vary by product, ranging from 1 to 6 sprays per nostril daily, with different frequencies for treatment and prevention purposes. The study period covers up to three months to assess both short-term and longer-term effects. During the study, participants or their parents will complete online questionnaires and follow healthcare providers advice on nasal wash techniques. Researchers will monitor nasal symptom changes, including intensity and frequency, improvement in nasal breathing, quality of life, and satisfaction with the sprays. Effectiveness will be evaluated from day 0 to day 5 for acute conditions and up to day 14 for chronic issues, extending to three months for seasonal symptom management. Safety, tolerance, and usage patterns will also be recorded throughout the study.

This research evaluates whether non-invasive vagal stimulation can better prevent chemotherapy-induced nausea in breast cancer patients undergoing cyclophosphamide and anthracycline treatment. Chemotherapy-induced nausea remains common and negatively impacts quality of life despite existing medications. Non-invasive vagal stimulation is approved for other conditions like headache and gastroparesis and may reduce nausea. Participants receive standard antiemetic treatment along with either active non-invasive auricular vagal stimulation or a sham stimulation twice daily, starting the day before chemotherapy until four days after, during the first three chemotherapy cycles. The stimulation uses a transcutaneous auricular device to assess if adding this method improves nausea control compared to standard care alone. Throughout the study, participants are monitored for nausea occurrence after each chemotherapy cycle, vomiting, use of rescue medications, emergency visits, hydration needs, and hospitalizations related to nausea. Quality of life questionnaires specific to breast cancer and general health are completed during the first three cycles. Safety and side effects related to vagal stimulation are also evaluated. The trial measures outcomes over up to 12 weeks, with primary focus on nausea after the first chemotherapy cycle.

Researchers are evaluating the safety and clinical performance of the Dexter Robotic System in patients undergoing robotic-assisted right colectomy. This study focuses on confirming the perioperative and early postoperative safety as well as the effectiveness of this robotic surgical system in these patients. The study involves performing a right colectomy using the Dexter robotic surgery system, which assists the surgeon during the operation. The procedure is robotic-assisted and aims to support surgical precision and control. There is a 30-day follow-up period after surgery to monitor outcomes. Participants will undergo the robotic-assisted right colectomy and will be monitored for safety for up to 30 days after the surgery. The study will assess primary safety outcomes during this period and evaluate efficacy during the surgery itself. Patients will have follow-up assessments according to standard care procedures to track recovery and any complications.

Researchers are conducting an ambispective, observational, multicenter, and multicohort study focusing on patients with non-small cell lung cancer NSCLC who are starting treatments with approved drugs developed by AstraZeneca or its alliance partners. The study includes three groups based on the stage of NSCLC resectable, unresectable, and metastatic. This modular study is designed to evaluate patients receiving these drugs once they have European marketing authorization and are available in the participating countries. Patients will be observed whether they have already received, are currently receiving, or will receive approved AstraZeneca drugs as monotherapy or in combination at any disease stage. The study tracks patients independently of treatment decisions made by their doctors. Each cohort represents a different stage of NSCLC, allowing specific assessment for each group. Participants will be followed to collect real-world data on outcomes such as disease-free survival, event-free survival, treatment failure times, response rates, progression-free survival, and overall survival over periods ranging from 3 to 5 years. Researchers will analyze treatment responses, recurrence-free survival, and treatment discontinuation times among other measures. The study involves no intervention from researchers on treatment plans and focuses on monitoring outcomes in routine clinical practice.